Biological markers of response for kidney cancer

To date, a reliable biomarker is yet to be discovered for the response of kidney cancer patients to treatment or for prognosis. In this review paper, Dr Robert Motzer and his research group from Memorial Sloan Kettering in the USA identified a set of 26 genes whose activity correlated with progression-free survival in the combination […]

read more

ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy

A study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program has identified several features of kidney cancer tumours that influence their response to immune checkpoint inhibitors, such as nivolumab and pembrolizumab. The research was conducted at the Dana-Farber Cancer Institute in America and is published in the journal, Nature Medicine. […]

read more

Molecular genetics of renal cell carcinoma

Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]

read more

NHS to fast-track cancer drugs that target genetic mutations

The NHS is preparing to fast-track the introduction of ‘game changing’ new cancer drugs that target tumours according to their genetic make-up. These revolutionary new treatments, called ‘tumour agnostic’ drugs, can be used against a wide range of cancers and could offer hope to patients with rare cancers that may previously have been untreatable. Tumour […]

read more

Genetic mutations associated with survival in immunotherapy-treated kidney cancer patients

A recent study of patients with solid tumours treated with immune checkpoint inhibitors has shown improved overall survival in patients who had mutations in the genes that code for a group of proteins involved in the way DNA is packaged in the cell (SWI and SNF genes, BRG1/hBRM-associated factor (BAF) and polybromo-BAF (PBAF)). The researchers […]

read more

ASCO GU 2019: When to obtain genetic testing for renal cell carcinoma

The following paper was presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Shuch provided a summary and guide to genetic testing for syndromic renal cell carcinoma (RCC). There is an established strong inheritance pattern in kidney cancer, and now there are 15+ recognised […]

read more
Showing all 6 results